The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade
This article was originally published in Scrip
Executive Summary
The drug development landscape has changed markedly over the 20 years since the EMA was founded in 1995, with a pronounced shift away from the blockbuster model to a more personalized approach involving diagnostic tools, more patient involvement, and the earlier availability of promising new drugs for unmet needs. Maureen Kenny and Ian Schofield spoke to Guido Rasi, former EMA executive director and now its principal adviser on strategy, about the complexity of the EU regulatory system, why it's OK to give companies scientific advice, and what the drug evaluation landscape might look like in the next 10-20 years.